Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil
Canada's MediPharm Labs has received a GMP certification from the Brazilian governing body, ANVISA. The approval allows for the production of active pharmaceutical ingredients (APIs) and end products for the Brazilian medical cannabis market. MediPharm has already received GMP certifications from the US FDA, the European Union, and Australia's TGA, and holds a drug establishment license from Health Canada. The Brazilian medical cannabis market is projected to reach CAD380m (USD282m) by 2025, according to industry forecasts. MediPharm Labs, which already produces two medical cannabis products with full ANVISA authorization for the Brazilian market, is potentially set for further product authorizations through the regulatory body, according to reports.
